AzarGen Biotechnologies

External Link:

https://azargen.com/

Thematic Focus:

Life Sciences and Health

Involved Countries:

Switzerland, South Africa

Is Affiliated to:

No items found

Received Funding By:

No items found

AzarGen, a biotechnology company in Stellenbosch, South Africa, develops recombinant human surfactant protein-B for respiratory diseases and a plant-made CD20-binding monoclonal antibody for autoimmune diseases using genetic engineering and synthetic biology in plants. Their proprietary synthetic DNA promoters enhance expression in genetically engineered plants for biomanufacturing biopharmaceuticals, biomaterials, cellular agriculture, and biofuels. AzarGen holds two patent families related to these technologies and is supported by the Industrial Development Corporation (IDC). Their management team has extensive expertise in plant biotechnology, genetic engineering, synthetic biology, and human genetics, with strategic guidance from an experienced advisory board. Mauritz Venter, Co-Founder & CEO, participated in the program 2013.